• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗生素后白细胞增强:用抗生素预处理的细菌对白细胞活性的敏感性增加。

Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes.

作者信息

McDonald P J, Wetherall B L, Pruul H

出版信息

Rev Infect Dis. 1981 Jan-Feb;3(1):38-44. doi: 10.1093/clinids/3.1.38.

DOI:10.1093/clinids/3.1.38
PMID:7012999
Abstract

Exposure of Escherichia coli and Staphylococcus aureus to high levels of certain antibiotics for brief periods of time increases the susceptibility of the organisms to the antimicrobial action of normal human leukocytes. The degree of sensitization varies with the antibiotic used for the pretreatment of the bacteria and is most pronounced in pretreatment of E. coli with chloramphenicol. Studies on the rates of phagocytosis and intracellular killing of E. coli indicate that the postantibiotic leukocyte enhancement effect operates through increased susceptibility of antibiotic-damaged bacteria to the intracellular killing mechanisms of leukocytes. These observations may explain the efficacy of antimicrobial dosage regimens in which drug levels are below inhibitory concentrations for part of the dosage interval.

摘要

将大肠杆菌和金黄色葡萄球菌短时间暴露于高浓度的某些抗生素下,会增加这些微生物对正常人白细胞抗菌作用的敏感性。致敏程度因用于预处理细菌的抗生素而异,在用氯霉素预处理大肠杆菌时最为明显。对大肠杆菌吞噬率和细胞内杀伤率的研究表明,抗生素后白细胞增强作用是通过抗生素损伤的细菌对白细胞细胞内杀伤机制的敏感性增加来实现的。这些观察结果可能解释了抗菌剂量方案的疗效,即在部分剂量间隔内药物水平低于抑制浓度。

相似文献

1
Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes.抗生素后白细胞增强:用抗生素预处理的细菌对白细胞活性的敏感性增加。
Rev Infect Dis. 1981 Jan-Feb;3(1):38-44. doi: 10.1093/clinids/3.1.38.
2
Enhanced susceptibility of Escherichia coli to intracellular killing by human polymorphonuclear leukocytes after in vitro incubation with chloramphenicol.体外与氯霉素孵育后,大肠杆菌对人多形核白细胞细胞内杀伤作用的敏感性增强。
Antimicrob Agents Chemother. 1981 Jun;19(6):945-51. doi: 10.1128/AAC.19.6.945.
3
Susceptibility of bacteria to serum lysis or phagocytosis following growth in subinhibitory levels of lincosaminide or spectinomycin related antibiotics.细菌在亚抑制水平的林可酰胺类或壮观霉素相关抗生素中生长后对血清溶解或吞噬作用的敏感性。
J Antibiot (Tokyo). 1986 Jul;39(7):978-84. doi: 10.7164/antibiotics.39.978.
4
Enhancement of the susceptibility of Staphylococcus aureus to phagocytosis after treatment with fosfomycin compared with other antimicrobial agents.与其他抗菌药物相比,磷霉素治疗后金黄色葡萄球菌对吞噬作用的敏感性增强。
Chemotherapy. 1995 Jan-Feb;41(1):45-9. doi: 10.1159/000239323.
5
Postantibiotic suppression of bacterial growth.抗生素后细菌生长抑制
Rev Infect Dis. 1981 Jan-Feb;3(1):28-37. doi: 10.1093/clinids/3.1.28.
6
Antimicrobial and Immunomodulatory Effect of Gum Arabic on Human and Bovine Granulocytes Against and .瓜尔胶对人和牛粒细胞抗 和 的抗菌及免疫调节作用。
Front Immunol. 2020 Jan 31;10:3119. doi: 10.3389/fimmu.2019.03119. eCollection 2019.
7
Enhanced susceptibility of Escherichia coli pretreated with RP7293 to leukocyte activity: comparison with other antimicrobial agents.用RP7293预处理的大肠杆菌对白细胞活性的敏感性增强:与其他抗菌剂的比较。
Chemotherapy. 1994 Mar-Apr;40(2):99-103. doi: 10.1159/000239179.
8
[Effect of antibiotics on intracellular bacteria. 2. Effect of antibiotic treatment on Staphylococcus aureus 209P phagocytized by mouse polymorphonuclear leukocytes].[抗生素对细胞内细菌的作用。2. 抗生素治疗对被小鼠多形核白细胞吞噬的金黄色葡萄球菌209P的作用]
Shigaku. 1985 Feb;72(5):1096-107.
9
Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones.在接触氨基糖苷类或喹诺酮类药物期间所选择的耐药菌的白细胞杀伤作用增强。
J Antimicrob Chemother. 1990 Jun;25(6):941-8. doi: 10.1093/jac/25.6.941.
10
[Biochemical processes in the leukocytes which phagocytize antibiotic--sensitive and antibiotic-resistant bacteria].[吞噬抗生素敏感菌和抗生素耐药菌的白细胞中的生化过程]
Antibiotiki. 1975;20(12):1107-11.

引用本文的文献

1
Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages.抗生素后白细胞增强介导巨噬细胞内细菌减少。
J Adv Res. 2024 Apr;58:117-128. doi: 10.1016/j.jare.2023.05.010. Epub 2023 Jun 7.
2
Antibiotics and ECMO in the Adult Population-Persistent Challenges and Practical Guides.成人人群中的抗生素与体外膜肺氧合——持续挑战与实用指南
Antibiotics (Basel). 2022 Mar 4;11(3):338. doi: 10.3390/antibiotics11030338.
3
A synthetic peptide sensitizes multi-drug resistant Pseudomonas aeruginosa to antibiotics for more than two hours and permeabilizes its envelope for twenty hours.
一种合成肽可使多药耐药铜绿假单胞菌对抗生素敏感超过两小时,并使其包膜通透性持续二十小时。
J Biomed Sci. 2020 Aug 6;27(1):85. doi: 10.1186/s12929-020-00678-3.
4
Pharmacological considerations for the proper clinical use of aminoglycosides.氨基糖苷类药物临床应用的药理学考虑因素。
Drugs. 2011 Dec 3;71(17):2277-94. doi: 10.2165/11597020-000000000-00000.
5
In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.头孢托罗在小鼠大腿和肺部感染模型中对多种细菌病原体的体内药效学研究。
Antimicrob Agents Chemother. 2008 Oct;52(10):3492-6. doi: 10.1128/AAC.01273-07. Epub 2008 Aug 1.
6
Setting and revising antibacterial susceptibility breakpoints.设定和修订抗菌药物敏感性断点
Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents. doi: 10.1128/CMR.00047-06.
7
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.重症监护中的抗菌药物给药:脓毒症的药代动力学、疾病程度及药效学
Clin Pharmacokinet. 2006;45(8):755-73. doi: 10.2165/00003088-200645080-00001.
8
Postantibiotic leukocyte enhancement of meropenem against gram-positive and gram-negative strains.美罗培南对革兰氏阳性和革兰氏阴性菌株的抗生素后白细胞增强作用。
Antimicrob Agents Chemother. 2000 Nov;44(11):3174-6. doi: 10.1128/AAC.44.11.3174-3176.2000.
9
Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?抗菌剂对吞噬细胞功能的干扰:免疫调节还是“免疫童话”?
Clin Microbiol Rev. 2000 Oct;13(4):615-50. doi: 10.1128/CMR.13.4.615.
10
Ambulatory use of parenteral antibacterials: contemporary perspectives.肠外抗菌药物的门诊使用:当代观点
Drugs. 2000;59 Suppl 3:1-8; discussion 47-9. doi: 10.2165/00003495-200059003-00001.